| Autor: |
Xudan Wang, Weiwei Cao, Yan Qiu, Hongchen Ji, Juzheng Yuan, Weikang Wu, Fuyuan Liu, Liangyong Feng, Rui Ding, Xiao Li, Kaishan Tao |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2023.1174999 |
| Popis: |
ObjectiveTo assess the efficacy and safety of camrelizumab plus different targeted drugs in adjuvant therapy after hepatocellular carcinoma (HCC) surgery.Patients and methodsThis retrospective cohort study included HCC patients who, after undergoing failed postoperative adjuvant lenvatinib therapy, received intravenous camrelizumab 200 mg every 3 weeks (C group, n = 97), camrelizumab plus oral apatinib 250 mg daily (C+A group, n = 125), camrelizumab plus oral lenvatinib 12 mg daily (for bodyweight ≥60 kg)/lenvatinib 8 mg daily (for bodyweight |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
